Market/Novel Tech

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have announced a collaboration to “discover, develop and commercialize new RNA interference (RNAi) therapeutics for… Read More »Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments